ANTIBODY-DERIVED T CELL ACTIVATING TECHNOLOGIES
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Mar 28, 2024
app pub date -
Feb 17, 2022
filing date -
Feb 18, 2021
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
Antibody derivatives are provided as binding partners. The binding partners bind to a one or a combination of antigens that include antigens present CD24, CD105 (endoglin), CD79 Beta (CD79b), and an antigen present in a CD3 T cell co-receptor. The antibody derivatives include single chain variable fragments (scFvs), Bi-specific T-cell engagers (BiTEs). Also provided are modified cells that express the binding partners, modified cells that secrete the binding partners, expression vectors that encode the binding partners, and methods of using the binding partners for treatment of a variety of cancers, autoimmune diseases, and modification of immune responses mounted to transplanted organs.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully